Initiation of a fixed-dose four-factor prothrombin complex concentrate protocol


Patients who require urgent warfarin reversal often receive four-factor prothrombin complex concentrate (4F-PCC), which is traditionally dosed according to weight and initial INR. Our institution implemented a fixed-dose 4F-PCC strategy, using an initial dose of 1500 units. We evaluated the frequency with which the initial fixed dose 4F-PCC was inadequate, as defined by need for supplemental dosing. As part of the protocol, if the initial fixed-dose 4F-PCC is administered and does not achieve INR goal, then the remainder of the standard weight- and INR-based dosing can be given. During the study period, 63 patients on warfarin received 4F-PCC using the fixed-dose protocol. Based on the INR following 4F-PCC administration, 11 patients (17%) were eligible to receive a supplemental dose based on failure to achieve their specified INR goal. Two of the 11 patients eligible for supplemental 4F-PCC dosing received the second dose, both with initial supratherapeutic INRs > 3.5. We found that most patients given an initial fixed-dose 4F-PCC achieved their INR goals, and of those who did not, most did not receive supplemental dosing, suggesting that clinical providers felt that adequate hemostasis had been achieved. In addition, fixed-dose 4F-PCC was able to be given rapidly, with few dosing errors, suggesting that this is a reasonable option for 4F-PCC delivery.

This is a preview of subscription content, log in to check access.


  1. 1.

    Corio JL, Sin JH, Hayes BD, Goldstein JN, Fuh L (2018) Impact of a pharmacist-driven prothrombin complex concentrate protocol on time to administration in patients with warfarin-associated intracranial hemorrhage. West J Emerg Med. 19(5):849–854

    Article  Google Scholar 

  2. 2.

    Tomaselli GF, Mahaffey KW, Cuker A et al (2017) 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 70(24):3042–3067

    Article  Google Scholar 

  3. 3.

    Klein L, Peters J, Miner J, Gorlin J (2015) Evaluation of fixed dose 4-factor prothrombin complex concentrate for emergent warfarin reversal. Am J Emerg Med 33(9):1213–1218

    Article  Google Scholar 

  4. 4.

    Varga C, Al-Touri S, Papadoukakis S, Caplan S, Kahn S, Blostein M (2013) The effectiveness and safety of fixed low-dose prothrombin complex concentrates in patients requiring urgent reversal of warfarin. Transfusion. 53(7):1451–1458

    CAS  Article  Google Scholar 

  5. 5.

    Abdoellakhan RA, Miah IP, Khorsand N, Meijer K, Jellema K (2017) Fixed versus variable dosing of prothrombin complex concentrate in vitamin K antagonist-related intracranial hemorrhage: a retrospective analysis. Neurocrit Care 26(1):64–69

    CAS  Article  Google Scholar 

  6. 6.

    Wozniak M, Kruit A, Padmore R, Giulivi A, Bormanis J (2012) Prothrombin complex concentrate for the urgent reversal of warfarin. Assessment of a standard dosing protocol. Transfus Apher Sci. 46:309–314

    Article  Google Scholar 

  7. 7.

    Khorsand N, Veeger NJ, van Hest RM, Ypma PF, Heidt J, Meijer K (2012) An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies. Haematologica 97(10):1501–1506

    CAS  Article  Google Scholar 

  8. 8.

    Frontera JA, Lewin JJ III, Rabinstein AA et al (2016) Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 24:6–46

    CAS  Article  Google Scholar 

  9. 9.

    Kcentra® [package insert]. Kankakee, IL: CSL Behring LLC; 2018

  10. 10.

    Hirri HM, Green PJ (2014) Audit of warfarin reversal using a new Octaplex reduced dose protocol. Transfus Apher Sci. 51(2):141–145

    CAS  Article  Google Scholar 

  11. 11.

    Astrup G, Sarangarm P, Burnett A (2018) Fixed dose 4-factor prothrombin complex concentrate for the emergent reversal of warfarin: a retrospective analysis. J Thromb Thrombolysis 45:300–305

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to L. Fuh.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fuh, L., Goldstein, J.N. & Hayes, B.D. Initiation of a fixed-dose four-factor prothrombin complex concentrate protocol. J Thromb Thrombolysis 50, 217–220 (2020).

Download citation


  • Four-factor prothrombin complex concentrate
  • Fixed-dose
  • Protocol
  • Supplemental dosing